Details of the Drug Formulations

General Information of Drug (ID: DMH0QKA)

Drug Name
GDC-0199 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Cross-matching ID
PubChem CID
49846579
ChEBI ID
CHEBI:133021
CAS Number
1257044-40-8
TTD ID
D00PBX
ACDINA ID
D00724

Full List of Drug Formulations Containing This Drug

Venetoclax 50 mg tablet
Company Formulation ID FDA Description
AbbVie F22154 Sodium stearyl fumarate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Polysorbate 80; Polyvinyl alcohol; Silicon dioxide; Copovidone k25-31; Polyethylene glycols
------------------------------------------------------------------------------------
Venetoclax 10 mg tablet
Company Formulation ID FDA Description
AbbVie F22152 Sodium stearyl fumarate; Anhydrous dibasic calcium phosphate; Ferric oxide yellow; Talc; Titanium dioxide; Polysorbate 80; Polyvinyl alcohol; Silicon dioxide; Copovidone k25-31; Polyethylene glycols
------------------------------------------------------------------------------------
Venetoclax 100 mg tablet
Company Formulation ID FDA Description
AbbVie F22153 Sodium stearyl fumarate; Anhydrous dibasic calcium phosphate; Ferric oxide yellow; Talc; Titanium dioxide; Polysorbate 80; Polyvinyl alcohol; Silicon dioxide; Copovidone k25-31; Polyethylene glycols
------------------------------------------------------------------------------------

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.